The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow Apr. 06, 2025 2:36 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock SNY , REGN 35 Comments 1 Like Stephen Ayers ...

Data & APIs. Events. Premarket ...

Eylea is locked in an intense fight for market share with Roche’s Vabysmo, which was launched in 2022. Last week, the Swiss company reported that worldwide third-quarter sales of Vabysmo were up ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1 ...

Recently, Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. If it gets a green light, as expected, the ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.

Regeneron has since countered with a high-dose (8 mg) version of Eylea. In the second quarter, Eylea HD accounted for $304 million of the $1.53 billion generated overall by the Eylea franchise.